Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease
Status:
Withdrawn
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II open-label study of the activity and safety of trastuzumab in patients
with vulvar Paget's disease with overexpression of HER2 on biopsy.